Can-Fite BioPharma (CANF) Prepaid Assets (2016 - 2025)
Can-Fite BioPharma's (CANF) quarterly Prepaid Assets came in at $900000.0 in Q4 2025, down 17.81% YoY from $1.1 million in Q4 2024, and down 22.95% on a QoQ basis from $1.2 million in Q2 2025.
Can-Fite BioPharma (CANF) Prepaid Assets (2016 - 2025) Analysis & Trends
Can-Fite BioPharma (CANF) has 10 years of Prepaid Assets data on file, last reported at $900000.0 in Q4 2025.
- Quarterly Prepaid Assets fell 17.81% year-over-year to $900000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $900000.0 (down 17.81% YoY) and the FY2025 annual result came in at $900000.0, down 17.81% from the prior year.
- Prepaid Assets fell to $900000.0 in Q4 2025, from $1.2 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $1.8 million in Q2 2022 to a low of $811000.0 in Q3 2021.
- A 5-year average of $1.2 million and a median of $1.1 million in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2021 — Prepaid Assets sank 51.08% — and 2022, when it soared 116.03%.
- Tracing CANF's Prepaid Assets over 5 years: stood at $929000.0 in 2021, then increased by 25.94% to $1.2 million in 2022, then slipped by 15.73% to $986000.0 in 2023, then rose by 11.05% to $1.1 million in 2024, then declined by 17.81% to $900000.0 in 2025.
- The last three Prepaid Assets figures came in at $900000.0 (Q4 2025), $1.2 million (Q2 2025), and $1.1 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Can-Fite BioPharma | 2.82 Mn | -8.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 900,000.00 |
| Jun 30, 2025 | 1.17 Mn |
| Dec 31, 2024 | 1.10 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Dec 31, 2023 | 986,000.00 |
| Sep 30, 2023 | 1.12 Mn |
| Jun 30, 2023 | 1.29 Mn |
| Mar 31, 2023 | 962,000.00 |
| Dec 31, 2022 | 1.17 Mn |
| Sep 30, 2022 | 1.75 Mn |
| Jun 30, 2022 | 1.82 Mn |
| Mar 31, 2022 | 971,000.00 |
| Dec 31, 2021 | 929,000.00 |
| Sep 30, 2021 | 811,000.00 |
| Jun 30, 2021 | 1.75 Mn |
| Mar 31, 2021 | 1.02 Mn |
| Dec 31, 2020 | 1.06 Mn |
| Jun 30, 2020 | 3.57 Mn |
| Dec 31, 2019 | 4.38 Mn |
| Sep 30, 2019 | 5.16 Mn |